Novartis AG
SIX:NOVN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
80.9944
102.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Novartis AG
Novartis AG
Income from Continuing Operations
Novartis AG
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novartis AG
SIX:NOVN
|
Income from Continuing Operations
$11.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
|
|
Roche Holding AG
SIX:ROG
|
Income from Continuing Operations
CHf12.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Income from Continuing Operations
$80m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Novartis AG
Glance View
Novartis AG, a global healthcare leader based in Switzerland, stands as a beacon of innovation in the pharmaceutical industry. With a rich history dating back to over a century, the company has evolved by focusing on developing innovative medicines and therapies that address serious health challenges across various therapeutic areas, including oncology, cardiovascular, neuroscience, and immunology. Novartis is particularly known for its commitment to research and development, consistently investing a significant portion of its revenue into discovering groundbreaking treatments. This strategy has yielded a robust portfolio of patented drugs, including blockbuster therapies that have transformed patient care and established Novartis as a dominant player in the market. For investors, Novartis presents a compelling opportunity nurtured by its strong financial performance, sustainable growth trajectory, and strategic focus on leveraging cutting-edge technology in drug discovery. The company enjoys a diversified revenue stream from both patented medicines and generics, thanks to its subsidiary Sandoz. Additionally, Novartis is actively engaging in transformative initiatives, such as adopting digital health solutions and pursuing gene therapies, positioning itself well for future growth in an increasingly competitive landscape. With a solid dividend history and a commitment to return value to shareholders, Novartis embodies the principles of sound investment, making it an appealing choice for those looking to invest in the burgeoning healthcare sector.
See Also
What is Novartis AG's Income from Continuing Operations?
Income from Continuing Operations
11.8B
USD
Based on the financial report for Sep 30, 2024, Novartis AG's Income from Continuing Operations amounts to 11.8B USD.
What is Novartis AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
1%
Over the last year, the Income from Continuing Operations growth was 21%. The average annual Income from Continuing Operations growth rates for Novartis AG have been 6% over the past three years , 10% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
